Literature DB >> 34536439

Smooth muscle cell CYB5R3 preserves cardiac and vascular function under chronic hypoxic stress.

Brittany G Durgin1, Katherine C Wood1, Scott A Hahn1, Brenda McMahon1, Jeffrey J Baust1, Adam C Straub2.   

Abstract

Chronic hypoxia is a major driver of cardiovascular complications, including heart failure. The nitric oxide (NO) - soluble guanylyl cyclase (sGC) - cyclic guanosine monophosphate (cGMP) pathway is integral to vascular tone maintenance. Specifically, NO binds its receptor sGC within vascular smooth muscle cells (SMC) in its reduced heme (Fe2+) form to increase intracellular cGMP production, activate protein kinase G (PKG) signaling, and induce vessel relaxation. Under chronic hypoxia, oxidative stress drives oxidation of sGC heme (Fe2+→Fe3+), rendering it NO-insensitive. We previously showed that cytochrome b5 reductase 3 (CYB5R3) in SMC is a sGC reductase important for maintaining NO-dependent vasodilation and conferring resilience to systemic hypertension and sickle cell disease-associated pulmonary hypertension. To test whether CYB5R3 may be protective in the context of chronic hypoxia, we subjected SMC-specific CYB5R3 knockout mice (SMC CYB5R3 KO) to 3 weeks hypoxia and assessed vascular and cardiac function using echocardiography, pressure volume loops and wire myography. Hypoxic stress caused 1) biventricular hypertrophy in both WT and SMC CYB5R3 KO, but to a larger degree in KO mice, 2) blunted vasodilation to NO-dependent activation of sGC in coronary and pulmonary arteries of KO mice, and 3) decreased, albeit still normal, cardiac function in KO mice. Overall, these data indicate that SMC CYB5R3 deficiency potentiates bilateral ventricular hypertrophy and blunts NO-dependent vasodilation under chronic hypoxia conditions. This implicates that SMC CYB5R3 KO mice post 3-week hypoxia have early stages of cardiac remodeling and functional changes that could foretell significantly impaired cardiac function with longer exposure to hypoxia.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  hypertrophy; hypoxia; nitric oxide; redox; smooth muscle cell; soluble guanylyl cyclase

Mesh:

Substances:

Year:  2021        PMID: 34536439      PMCID: PMC8766905          DOI: 10.1016/j.yjmcc.2021.09.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  49 in total

1.  Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo.

Authors:  Christiane Rothkegel; Peter M Schmidt; Derek-John Atkins; Linda Sarah Hoffmann; Harald H H W Schmidt; Henning Schröder; Johannes-Peter Stasch
Journal:  Mol Pharmacol       Date:  2007-08-22       Impact factor: 4.436

2.  Human recombinant soluble guanylyl cyclase: expression, purification, and regulation.

Authors:  Y C Lee; E Martin; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  Cyclic GMP in Vascular Relaxation: Export Is of Similar Importance as Degradation.

Authors:  Christian Krawutschke; Doris Koesling; Michael Russwurm
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-07-23       Impact factor: 8.311

Review 4.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

5.  Hemoglobin α/eNOS coupling at myoendothelial junctions is required for nitric oxide scavenging during vasoconstriction.

Authors:  Adam C Straub; Joshua T Butcher; Marie Billaud; Stephanie M Mutchler; Mykhaylo V Artamonov; Anh T Nguyen; Tyler Johnson; Angela K Best; Megan P Miller; Lisa A Palmer; Linda Columbus; Avril V Somlyo; Thu H Le; Brant E Isakson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-10-02       Impact factor: 8.311

6.  Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling.

Authors:  Mizanur M Rahaman; Anh T Nguyen; Megan P Miller; Scott A Hahn; Courtney Sparacino-Watkins; Soma Jobbagy; Nolan T Carew; Nadiezhda Cantu-Medellin; Katherine C Wood; Catherine J Baty; Francisco J Schopfer; Eric E Kelley; Mark T Gladwin; Emil Martin; Adam C Straub
Journal:  Circ Res       Date:  2017-06-05       Impact factor: 17.367

7.  The relationship between the components of pulmonary artery pressure remains constant under all conditions in both health and disease.

Authors:  Raheel Syyed; John T Reeves; David Welsh; David Raeside; Martin K Johnson; Andrew J Peacock
Journal:  Chest       Date:  2007-11-07       Impact factor: 9.410

8.  Hypoxia-inducible factor-1α in pulmonary artery smooth muscle cells lowers vascular tone by decreasing myosin light chain phosphorylation.

Authors:  Yu-Mee Kim; Elizabeth A Barnes; Cristina M Alvira; Lihua Ying; Sushma Reddy; David N Cornfield
Journal:  Circ Res       Date:  2013-03-19       Impact factor: 17.367

9.  Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.

Authors:  Diana Bonderman; Ingrid Pretsch; Regina Steringer-Mascherbauer; Pavel Jansa; Stephan Rosenkranz; Caroline Tufaro; Andja Bojic; Carolyn S P Lam; Reiner Frey; Michael Ochan Kilama; Sigrun Unger; Lothar Roessig; Irene M Lang
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

Review 10.  The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases.

Authors:  Hajime Abe; Hiroaki Semba; Norihiko Takeda
Journal:  J Atheroscler Thromb       Date:  2017-07-28       Impact factor: 4.928

View more
  1 in total

1.  Loss of cardiomyocyte CYB5R3 impairs redox equilibrium and causes sudden cardiac death.

Authors:  Nolan T Carew; Heidi M Schmidt; Shuai Yuan; Joseph C Galley; Robert Hall; Helene M Altmann; Scott A Hahn; Megan P Miller; Katherine C Wood; Bethann Gabris; Margaret C Stapleton; Sean Hartwick; Marco Fazzari; Yijen L Wu; Mohamed Trebak; Brett A Kaufman; Charles F McTiernan; Francisco J Schopfer; Placido Navas; Patrick H Thibodeau; Dennis M McNamara; Guy Salama; Adam C Straub
Journal:  J Clin Invest       Date:  2022-09-15       Impact factor: 19.456

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.